Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05086289 · ClinicalTrials.gov registry record · Phase 2

Chronic Pain Master Protocol (CPMP): A Study of LY3526318 in Participants With Chronic Low Back Pain

A Phase 2 study of Chronic Low Back Pain, sponsored by Eli Lilly and Company.

Completed
Registry status
Phase 2
Development phase
159
Enrollment target
20
Study locations

NCT05086289 is a Phase 2 study of Chronic Low Back Pain that has completed, run by Eli Lilly and Company. The registered enrollment target is 159 participants, below the 590-participant average among 71 other Chronic Low Back Pain trials with a reported enrollment target (73% lower). The trial reports 20 study locations across 8 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05086289, a Phase 2 study of Chronic Low Back Pain, has completed, sponsored by Eli Lilly and Company.

COMPLETED
Registry status
Phase 2
Development phase
159 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to test whether LY3526318 is efficacious and safe in relieving chronic low back pain (CLBP). This trial is part of the chronic pain master protocol H0P-MC-CPMP (NCT05986292) which is a protocol to accelerate the development of new treatments for chronic pain.

Conditions Studied

Chronic Low Back Pain

Interventions

  • DRUG Placebo
  • DRUG LY3526318

Study Locations (20)

Florida

  • VIN-Julie Schwartzbard - Aventura
  • Suncoast Research Group - Miami
  • New Horizon Research Center - Miami
  • Renstar Medical Research - Ocala
  • Synexus Clinical Research US, Inc - Orlando - Orlando
  • Synexus Clinical Research US, Inc. - Pinellas Park
  • Synexus Clinical Research US, Inc. - The Villages

Arizona

  • Synexus- Chandler - Chandler
  • Synexus Clinical Research - Glendale - Glendale
  • Alliance for Multispecialty Research, LLC Tempe - Tempe

Massachusetts

  • Boston Clinical Trials - Boston
  • ActivMed Practices and Research - Methuen
  • MedVadis Research Corporation - Waltham

California

  • Artemis Institute for Clinical Research - Riverside
  • Artemis Institute for Clinical Research - San Diego

Illinois

  • Synexus Clinical Research US, Inc. - Chicago
  • Northwestern University - Chicago

Connecticut

  • CMR of Greater New Haven - Hamden

Idaho

  • Rocky Mountain Clinical Research - Idaho Falls

Michigan

  • Great Lakes Research Group, Inc. - Bay City

Trial Details

FieldValue
Enrollment Target 159 participants
Start Date 2021-10-25
Est. Completion 2022-06-17
Phase Phase 2

Sponsor

Eli Lilly and Company

1,341 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05086289

The ClinicalTrials.gov registry entry for NCT05086289 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 159 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 590-participant average among 71 other Chronic Low Back Pain trials with a reported enrollment target (73% lower). The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Chronic Low Back Pain appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT05086289 reports 20 study locations spanning 8 distinct geographic areas - top geographies include Florida, Arizona, Massachusetts.

Frequently Asked Questions

What is clinical trial NCT05086289 about?

NCT05086289 is a clinical study titled "Chronic Pain Master Protocol (CPMP): A Study of LY3526318 in Participants With Chronic Low Back Pain". The purpose of this study is to test whether LY3526318 is efficacious and safe in relieving chronic low back pain (CLBP). This trial is part of the chronic pain master protocol H0P-MC-CPMP (NCT05986292) which is a protocol to accelerate the development of new treatments for chronic pain.

What is the current status of trial NCT05086289?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 159 participants. The study started on 2021-10-25. Estimated completion is 2022-06-17.

What conditions does trial NCT05086289 study?

This clinical trial studies the following conditions: Chronic Low Back Pain.

What interventions are being tested in trial NCT05086289?

The interventions under investigation include: Placebo (DRUG), LY3526318 (DRUG).

Who is sponsoring clinical trial NCT05086289?

This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05086289 being conducted?

This trial has 20 study locations across Arizona, California, Connecticut, Florida, Idaho. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Chronic Low Back Pain

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Chronic Low Back Pain

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.